Will Eli Lilly beat Wall Street's $6.71 earnings estimate when it reports Aug 5?
100% of users predicted YES — the community got this one right. 2 predictions cast.
Eli Lilly beat Wall Street's earnings estimate when it reported second-quarter 2026 results on Aug. 5. The company posted adjusted diluted earnings per share of $8.38, well above analyst consensus estimates that ranged from roughly $6.07 to $6.71 depending on the data provider, on revenue of $23.0 billion, up 48% from a year earlier. Lilly also raised its full-year revenue guidance to a range of $85 billion to $87 billion from a prior forecast of $82 billion to $85 billion. The beat was driven by continued demand for its diabetes and weight-loss drugs: Mounjaro revenue rose 91% to $9.9 billion, and Zepbound generated $4.9 billion in U.S. sales, a 44% year-over-year gain. The results extended Lilly's run of outperformance tied to the GLP-1 drug category, which has helped push its market value to among the highest in the pharmaceutical sector over the past two years. Community forecasters unanimously predicted the beat, matching the actual outcome, though the market consisted of only two recorded votes.